touchIMMUNOLOGY touchIMMUNOLOGY
Alopecia Areata

Brett King: JAK Inhibitors in the Treatment of Alopecia Areata

Copy Link
Published Online: Oct 5th 2021

Touch Medical Media coverage of data presented at EADV 2021:

It was an absolute pleasure to be able to speak with Dr Brett King (Yale School of Medicine, New Haven, CT, USA) about the recent efficacy and safety results presented around the JAK inhibitors, baricitinib and ritlecitinib, in the treatment of alopecia areata. 

His presentations entitled ‘Efficacy and Safety of Ritlecitinib (PF-06651600) in Patients with Alopecia Areata and ≥50% Scalp Hair Loss: Results from the International ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Study‘ and ‘Efficacy and safety of baricitinib in adults with alopecia areata: Phase 3 results from two randomized controlled trials (BRAVE-AA1 and BRAVE-AA2)‘ were given at the EADV 30th Congress, 29 Sep – 2 Oct.

Questions

  1. Could you tell us a little about the ALLEGRO and BRAVE clinical trials, their design and patient populations? (0:14)
  2. What were the efficacy and safety findings from these studies and how do they compare? (1:47)
  3. With two JAK inhibitors appearing promising in this indication, what are their relative strengths and limitations? (3:47)

Disclosures: Dr. Brett King has served on advisory boards and/or is a consultant and/or is a clinical trial investigator for Abbvie, Aclaris Therapeutics Inc, AltruBio Inc, Almirall, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Myers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences Inc, Eli Lilly and Company, Incyte Corp, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio. He is on speaker bureaus for Pfizer Inc, Regeneron and Sanofi Genzyme

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.

Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.

This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

Related Videos In Alopecia Areata
Alopecia Areata
Brett King: JAK Inhibitors in the Treatment of Alopecia Areata

It was an absolute pleasure to be able to speak with Dr Brett King (Yale School of Medicine, New Haven, CT, USA) about the recent efficacy and safety results presented around the JAK inhibitors, baricitinib and ritlecitinib, in the treatment of alopecia areata.  His presentations entitled 'Efficacy and Safety of Ritlecitinib (PF-06651600) in Patients with Alopecia Areata and ≥50% Scalp Hair Loss: Results from the International ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Study' and 'Efficacy and safety of baricitinib in adults with alopecia areata: Phase 3 results from two randomized controlled trials (BRAVE-AA1 and BRAVE-AA2)' were given at the EADV 30th Congress, 29 Sep - 2 Oct. Questions Could you tell us a little about the ALLEGRO and BRAVE clinical trials, their design and patient populations? (0:14) What were the efficacy and safety findings from these studies and how do they compare? (1:47) With two JAK inhibitors appearing promising in this indication, what are their relative strengths and limitations? (3:47) Disclosures: Dr. Brett King has served on advisory boards and/or is a consultant and/or is a clinical trial investigator for Abbvie, Aclaris Therapeutics Inc, AltruBio Inc, Almirall, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Myers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences Inc, Eli Lilly and Company, Incyte Corp, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio. He is on speaker bureaus for Pfizer Inc, Regeneron and Sanofi Genzyme Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival. Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72